Breaking News Instant updates and real-time market news.

IONS

Ionis Pharmaceuticals

$52.15

0.23 (0.44%)

, JNJ

Johnson & Johnson

$115.31

-0.35 (-0.30%)

07:01
12/22/16
12/22
07:01
12/22/16
07:01

Ionis earns milestone payment from Janssen for advancing new program under deal

Ionis Pharmaceuticals (IONS) announced that it has earned $5M milestone payment from Janssen Biotech (JNJ) associated with the validation of an undisclosed target to treat patients with a gastrointestinal autoimmune disease. Under the collaboration, Ionis and Janssen will continue to evaluate the target with the goal of advancing an antisense drug into development. Under the terms of the agreement, which covers three programs, Ionis is eligible to receive nearly $800M in development, regulatory and sales milestone payments and license fees. In addition, Ionis will receive tiered royalties that on average are double-digits on sales from any product that is successfully commercialized.

IONS

Ionis Pharmaceuticals

$52.15

0.23 (0.44%)

JNJ

Johnson & Johnson

$115.31

-0.35 (-0.30%)

  • 05

    Jan

  • 09

    Jan

  • 01

    Feb

IONS Ionis Pharmaceuticals
$52.15

0.23 (0.44%)

11/07/16
JPMS
11/07/16
NO CHANGE
JPMS
Neutral
JPMorgan still views Ionis as fairly valued
JPMorgan analyst Jessica Fye believes the data today continue to "derisk and solidify" Spinraza's clinical profile. The analyst, however, thinks it will be difficult to lift the overhang around platelet adverse events. She continues to view Ionis Pharmaceuticals as fairly valued and keeps a Neutral rating on the shares. Ionis is up 18% to $32.10 in afternoon trading.
12/20/16
BMOC
12/20/16
NO CHANGE
BMOC
Ionis Pharmaceuticals price target raised to $61 from $48 at BMO Capital
BMO Capital analyst Do Kim raised the price target on Ionis after positive Phase III data for its Volanesorsen drug was reported. The analyst says the data improves the chances of success for two upcoming pivotal studies, and Kim thinks that the risk/reward ratio for the company's January 5 Analyst Day is positive. Kim keeps an Outperform rating on the shares.
12/21/16
PIPR
12/21/16
NO CHANGE
PIPR
Piper lays out top BioPharma picks for 2017
Piper Jaffray analysts laid out their top BioPharma picks for 2017. Analyst Richard Purkiss favors Pfizer (PFE) and Eli Lilly (LLY) as his top large pharma picks. Analyst Joshua Schimmer calls Gilead (GILD) and Alexion (ALXN) his top large cap picks. Analyst David Amsellem names Horizon Pharma (HZNP) his top specialty pharma pick. Piper's other top Biopharma picks for 2017 include ACADIA (ACAD), Aimmune (AIMT), Akorn (AKRX), Alnylam (ALNY), Axovant Sciences (AXON), Cara Therapeutics (CARA), CoLucid Pharmaceuticals (CLCD), Eale Pharmaceuticals (EGRX), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), Neurocrine (NBIX), Nektar (NKTR), Otonomy (OTIC), Reata Pharmaceuticals (RETA), Rigel Pharmaceuticals (RIGL), Ignyta (RXDX), Theravance Biopharma (TBPH), Versartis (VSAR) and Voyager Therapeutics (VYGR). The analysts look for recent momentum in BioPharma to continue in 2017. They believe innovation and potentially repatriation should lead to increased merger activity.
12/21/16
PIPR
12/21/16
NO CHANGE
PIPR
Gilead buying Alexion tops Piper's potential events in 2017
Piper Jaffray healthcare analysts, led by Joshua Schimmer, laid out 17 potential surprise or provocative events for Biopharma in 2017. Their potential outcomes and events are led Gilead (GILD) acquiring Alexion (ALXN) and a President Donald Trump tweeting about the price of Biogen and Ionis Pharmaceuticals' (IONS) Spinraza. Other potential events Piper sees is a "massively dilutive" equity recapitalization for Valeant (VRX) and a failure for Seattle Genetics' (SGEN) ECHELON trial. The firm also sees the potential for Teva cleaning house and bringing in a non-Israeli CEO.
JNJ Johnson & Johnson
$115.31

-0.35 (-0.30%)

11/29/16
LEHM
11/29/16
DOWNGRADE
Target $125
LEHM
Equal Weight
Johnson & Johnson downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoff Meacham downgraded Johnson & Johnson to Equal Weight and lowered its price target to $125 from $130. The analyst said risk/reward is less compelling and said shares could become a source of funds due to Remicade biosimilar risk, slowing med tech utilization, reduced pipeline impact, and a move away from defensive names.
11/29/16
11/29/16
DOWNGRADE

On The Fly: Top five analyst downgrades
On The Fly: Top five analyst downgrades: 1. Wendy's (WEN) downgraded to Neutral from Buy at Goldman with analyst Karen Holthouse citing valuation with the stock up 23% over the past month. 2. SAIC (SAIC) downgraded to Neutral from Buy at Citi with analyst Jonathan Raviv citing the recent rally in the shares and some overhang from the pending contract transition. 3. BioMarin (BMRN), Johnson & Johnson (JNJ), and Vertex (VRTX) were downgraded to Equal Weight from Overweight at Barclays. 4. Nivalis Therapeutics (NVLS) downgraded to Market Perform Raymond James, to Hold from Buy at Stifel, to Market Perform from Outperform at Cowen, and to Neutral from Outperform at Baird. 5. U.S. Steel (X) downgraded to Hold from Buy at Argus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/02/16
GSCO
12/02/16
NO CHANGE
Target $82
GSCO
Buy
Jardiance CV death risk reduction indication a positive for Lilly, says Goldman
Goldman Sachs analyst Jami Rubin said his estimate, and the current consensus estimate, for Jardiance sales assumed that Eli Lilly (LLY) would get a new indication for Jardiance to reduce the risk of cardiovascular death in type 2 diabetes patients, but he still views the news as positive for sentiment given some investor nervousness and the recent solanezumab disappointment. The indication differentiates Jardiance from Johnson & Johnson's (JNJ) Invokana and AstraZeneca's (AZN) Farxiga, adds Rubin, who has a Buy rating and $82 price target on Lilly shares.
12/20/16
UBSW
12/20/16
NO CHANGE
UBSW
Neutral
Sanofi strategy for Actelion acquisition not clear, says UBS
UBS analyst Jack Scannell provided thoughts on the potential Sanofi (SNY) acquisition of Actelion (ALIOY) after Johnson & Johnson (JNJ) dropped out of the bidding. The reason JNJ backed out was it did not believe it could enhance shareholder value with the deal and Scannell believes the same could be said for Sanofi. He does see a path to accretive earnings in a cash and stock deal and if Sanofi could delever from its EBITDA level within a year. Scannell, however, said the strategic reasons for the deal remain unclear and could raise questions about Sanofi's overall strategy.

TODAY'S FREE FLY STORIES

IBM

IBM

$148.97

-0.15 (-0.10%)

09:10
11/18/17
11/18
09:10
11/18/17
09:10
Periodicals
IBM could be next to fetch higher valuation, Barron's says »

Investors are warming to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

GE

General Electric

$18.21

-0.04 (-0.22%)

09:05
11/18/17
11/18
09:05
11/18/17
09:05
Periodicals
Option play offer some help given GE dividend, depressed stock, Barron's says »

While wagering against…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.21

-0.04 (-0.22%)

09:00
11/18/17
11/18
09:00
11/18/17
09:00
Periodicals
Risk remains after GE dividend cut, Barron's says »

While buying General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$88.72

0.71 (0.81%)

, T

AT&T

$34.51

-0.01 (-0.03%)

08:21
11/18/17
11/18
08:21
11/18/17
08:21
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

TWX

Time Warner

$88.72

0.71 (0.81%)

T

AT&T

$34.51

-0.01 (-0.03%)

NYT

New York Times

$17.65

0.05 (0.28%)

TEX

Terex

$44.82

0.8 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

TPIC

TPI Composites

$19.06

-0.97 (-4.84%)

07:25
11/18/17
11/18
07:25
11/18/17
07:25
Conference/Events
TPI Composites to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SYNA

Synaptics

$38.21

0.57 (1.51%)

04:55
11/18/17
11/18
04:55
11/18/17
04:55
Conference/Events
Synaptics management to meet with KeyBanc »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 06

    Dec

WGL

WGL Holdings

$84.32

-0.14 (-0.17%)

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Earnings
WGL Holdings reports Q4 adjusted EPS (17c), consensus (19c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

, LMOS

Lumos Networks

17:58
11/17/17
11/17
17:58
11/17/17
17:58
Hot Stocks
Tactile Systems to replace Lumos Networks in S&P 600 at open on 11/22 »

EQT Infrastructure…

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

, MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

17:56
11/17/17
11/17
17:56
11/17/17
17:56
Hot Stocks
Breaking Hot Stocks news story on Invesco Mortgage, MKS Instruments »

Invesco Mortgage to…

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

17:55
11/17/17
11/17
17:55
11/17/17
17:55
Hot Stocks
MKS Instruments to replace Brocade in S&P 400 at open on 11/22 »

S&P 500 constituent…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

UQM

UQM Technologies

$1.18

0.015 (1.29%)

17:24
11/17/17
11/17
17:24
11/17/17
17:24
Syndicate
Breaking Syndicate news story on UQM Technologies »

UQM Technologies files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$238.02

-1.35 (-0.56%)

17:23
11/17/17
11/17
17:23
11/17/17
17:23
Periodicals
Goldman Sachs has $510M lawsuit dismissed, Reuters reports »

A $510M lawsuit that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VICL

Vical

$1.94

-0.02 (-1.02%)

17:18
11/17/17
11/17
17:18
11/17/17
17:18
Hot Stocks
Breaking Hot Stocks news story on Vical »

Biotechnology Value Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:18
11/17/17
11/17
17:18
11/17/17
17:18
Hot Stocks
Ligand director sells 5,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:17
11/17/17
11/17
17:17
11/17/17
17:17
Hot Stocks
Ligand CFO sells 6,559 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:17
11/17/17
11/17
17:17
11/17/17
17:17
Hot Stocks
Ligand CEO sells 5,269 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBI

MBIA

$9.01

0.13 (1.46%)

17:15
11/17/17
11/17
17:15
11/17/17
17:15
Hot Stocks
Breaking Hot Stocks news story on MBIA »

Fine Capital Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBCN

Rubicon

$8.07

0.1218 (1.53%)

17:03
11/17/17
11/17
17:03
11/17/17
17:03
Hot Stocks
Breaking Hot Stocks news story on Rubicon »

Bandera Partners reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANCB

Anchor Bancorp

$24.75

-0.1 (-0.40%)

17:02
11/17/17
11/17
17:02
11/17/17
17:02
Hot Stocks
Anchor Bancorp announces stock repurchase program, 10b5-1 trading plan »

Anchor Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIFI

Gulf Island Fabrication

$12.30

-0.1 (-0.81%)

16:58
11/17/17
11/17
16:58
11/17/17
16:58
Syndicate
Breaking Syndicate news story on Gulf Island Fabrication »

Gulf Island Fabrication…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPB

Mid Penn Bancorp

$31.09

0.59 (1.93%)

16:51
11/17/17
11/17
16:51
11/17/17
16:51
Hot Stocks
Mid Penn Bancorp, Scottdale shareholders approve merger »

Mid Penn Bancorp and The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CALD

Callidus Software

$28.95

0.3 (1.05%)

16:49
11/17/17
11/17
16:49
11/17/17
16:49
Initiation
Callidus Software initiated at First Analysis »

Callidus Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIFI

Gulf Island Fabrication

$12.30

-0.1 (-0.81%)

16:46
11/17/17
11/17
16:46
11/17/17
16:46
Hot Stocks
Breaking Hot Stocks news story on Gulf Island Fabrication »

Piton Capital Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.21

-0.04 (-0.22%)

16:42
11/17/17
11/17
16:42
11/17/17
16:42
Hot Stocks
General Electric CEO acquires 60,000 common shares »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.